Improving immune response against triple negative breast cancer
Enhancing Tumor Cell Immunogenicity using Improved Molecules Targeting Chromatin Remodeling
This study is exploring a new way to help the immune system fight advanced triple negative breast cancer by using a mix of treatments that target specific proteins and genes, and it's being tested in mice to see how well it works.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11000795 on NIH RePORTER |
What this research studies
This research investigates a new approach to enhance the immune response against advanced stage triple negative breast cancer (TNBC) by combining specific chemotherapies with targeted therapies that affect chromatin remodeling. The study focuses on inhibiting a protein called BPTF, which plays a role in regulating gene expression, to boost the immunogenicity of tumor cells. By using a combination of BPTF inhibition and a DNA methyl transferase inhibitor, researchers aim to stimulate the immune system to better recognize and attack TNBC cells. This approach is being tested in mouse models to evaluate its effectiveness in controlling tumor growth.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with advanced stage triple negative breast cancer who are seeking new treatment options.
Not a fit: Patients with early-stage breast cancer or those with other types of cancer may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced triple negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in enhancing tumor immunogenicity through similar approaches, indicating potential for success in this novel combination therapy.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Landry, Joseph William — Virginia Commonwealth University
- Study coordinator: Landry, Joseph William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.